Publication: Discovery of novel CYP17 inhibitors for the treatment of prostate cancer with structure-based drug design
Loading...
Program
Organization Authors
Co-Authors
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.
Source
Publisher
Bentham Science Publishers
Subject
Citation
item.page.haspartof
Source
Letters in Drug Design and Discovery
item.page.ispartofseries
item.page.edition
DOI
10.2174/1570180810906050337
item.page.datauri
item.page.link
Rights
N/A
Copyrights Note
Rights and licensing
N/A